When: Confirmed break above $429 (10 EMA) with MACD histogram turning positive

Then: Deploy remaining dry powder

When: Oil breaks above $105

Then: Close position entirely

When: Polymarket recession odds spike above 15%

Then: Close position entirely

When: MACD line crosses below signal line before tier-1 confirmation

Then: Pause new adds until cross reverses or sell-side confirmation materializes

HOLD / UNDERWEIGHT - Support a buy with dramatically reduced initial allocation (15-20% of target vs proposed 50%) and strict confirmation gates before adding

• Market may be correctly pricing scientific doubt about Lp(a) reduction thesis given pelacarsen's failure to show CV outcomes benefit at 70% reduction, creating legitimate uncertainty about whether even 95% reduction will matter
• Probability math favors waiting: 70% probability of success at $396 confirmation entry is mathematically superior to 50% probability at $395 entry, per the asymmetric risk-taking foundation
• Backward-looking Q2 2026 results (record quarter, strong FCF, excellent margins) are being repriced on forward-looking pipeline impairment event; peak sales probability-weighted need to be reassessed
• AMGN carries $57.3 billion in total debt against $11.7 billion in equity (490% debt-to-equity ratio); high-leverage amplifies equity downside on pipeline NPV compression
• Technical capitulation claim challenged: RSI at 37.4 (oversold-adjacent but NOT below 30), bearish wide-range candle closing near low (not reversal pattern), MACD histogram at -4.71 with bear cross pending, 50 SMA lost intraday
• ATR expansion to 27% jump means volatility and uncertainty are increasing, not decreasing; widening stops in high-volatility environment gives trade more room to be wrong
• Defined risk to 200 SMA at $354.51 from $395 entry is $40.49/share (10.25% downside on 50% allocation); fully loaded average cost near $400 with $46 risk per share to stop is worse than 1:1 reward-to-risk on probability-weighted basis
• Macro headwinds: Polymarket pricing 93% probability of NO Fed rate cuts in 2026, oil at $100 on geopolitical tensions (Houthi strikes, US-Iran), climbing 10-year yield compresses long-duration biotech multiples
• AMGN beta of 0.43 already violated by 10% one-day move on supposedly defensive name; backward-looking statistical measure not reliable in current regime
• No institutional accumulation evidence, no tier-1 sell-side confirmation of differentiation thesis, RSI not below 30, bear cross not confirmed, 50 SMA not reclaimed, Reddit silent (historically means bottom not in) - all confirmation conditions unmet
• Conservative alternative: 15-20% of target weight initial position sized so worst-case loss to 200 SMA stop is max 0.5% of total portfolio NAV; add second tranche only on confirmed close above 10 EMA at $429 with positive MACD histogram and tier-1 sell-side support
• Macro kill switch: close position if oil breaks above $105 or Polymarket recession odds spike above 15%; maximum 10 trading session holding period for initial tranche if confirmation does not materialize

→ vs aggressive: Challenges 'mechanical mispricing' narrative: market may be correctly pricing scientific doubt given pelacarsen's failure to show CV outcomes benefit at 70% reduction, creating legitimate uncertainty about whether even 95% reduction will matter

→ vs aggressive: Challenges 'timing argument': 70% probability of success at $396 confirmation entry is mathematically superior to 50% probability at $395 entry; optimizing for conditional probability, not entry price

→ vs aggressive: Challenges 'fundamentals argument': anchoring to backward-looking Q2 results while stock is being repriced on forward-looking pipeline impairment event; $57.3B debt vs $11.7B equity (490% D/E) amplifies equity downside

→ vs aggressive: Challenges 'technical capitulation claim': RSI at 37.4 (not below 30), bearish wide-range candle (not reversal pattern), MACD bear cross pending, 50 SMA lost intraday - not capitulation, downside trend in early innings

→ vs aggressive: Challenges 'ATR expansion argument': 27% ATR jump means uncertainty increasing, not decreasing; widening stops gives trade more room to be wrong

→ vs aggressive: Challenges 'macro argument': 93% Polymarket probability of NO Fed cuts in 2026 is terrible for long-duration biotech; oil at $100 extends hawkish regime; AMGN beta of 0.43 already violated by 10% one-day move

→ vs aggressive: Challenges 'alternative deployment' argument: cash is a position earning real yield in 4%+ money market environment; opportunity cost of waiting is bounded and known while cost of being wrong is asymmetric and potentially large

BUY at 30% initial allocation with staged confirmation criteria; add second tranche on close above $401 with declining volume, RSI above 45, and tier-1 sell-side support; reserve remaining 30% for break above $429; apply 1.5% portfolio-at-risk cap, macro kill switches at 15% recession odds or $105 oil, and conditional MACD bear cross delay rule

• 30% initial allocation balances Aggressive (50%) and Conservative (15-20%) positions
• Initiate at $395; $40.49/10.25% downside to 200 SMA at $354.51 structural floor
• Add second tranche on confirmed close above $401 (lower Bollinger band) with declining volume, RSI recovering above 45, and at least one tier-1 sell-side differentiation note
• Remaining 30% deployed only on clean break above $429 (10 EMA) with full thesis validation
• MACD histogram at -4.71 with pending bear cross - delay entry if cross completes before initiation
• Fundamentals strong: $8.65B FCF, 45% EBITDA margins, 16x forward P/E, 2.3% dividend yield
• Net debt declined $4.9B in past year; long-term trend intact with rising 200 SMA
• Macro kill switches: 15% recession odds (regime shift) and $105 oil price
• Replace Conservative's 10-session auto-exit with 15-session review checkpoint
• 1.5% maximum portfolio-at-risk constraint limits position sizing
• UBS published differentiation note within hours; AMGN Phase 3 data was positive with different mechanism than failed peer
• Tier-1 sell-side confirmation expected within 48 hours in event-driven crash patterns, not necessarily 15-20% higher entry

→ vs aggressive: 50% allocation too aggressive given broken technical structure with RSI at 37.4, bearish candle closing near low, and pending MACD bear cross; 10.25% downside to stop means 5% portfolio impact, exceeding prudent risk parameters

→ vs aggressive: Claim of 'textbook capitulation' lacks evidence - no confirmed RSI below 30, reversal candle structure, or volatility climax; pattern-matching to narrative rather than reading actual tape

→ vs aggressive: Close above $396 with declining volume is too lenient for broken technical; single-session 50 SMA reclaim after record-volume breakdown historically has high failure rate

→ vs conservative: 15-20% initial allocation too small given asymmetric fundamentals, defined $354.51 technical floor, and credible UBS scientific counter-thesis already published

→ vs conservative: Forward P/E of 16x is meaningful for defensive pharma with growing earnings and high FCF; claiming it's 'meaningless' is incorrect

→ vs conservative: Backward-looking beta of 0.43 already violated by 10% one-day move; overstates protection value

→ vs conservative: Probability-weighted math has made-up inputs; 70% success rate is not independently verified

→ vs conservative: 10-session maximum hold is too rigid; AMGN's strong fundamentals warrant patience and modified review checkpoint rather than automatic date-based exit